EGFR and cancer: Compared with mice with mutated hKRAS, the EGFR (Del19) mice showed a much lower cancer burden and a longer process from initiation to early development of adenocarcinoma,80,81 which is conducive to observing the occurrence of carcinoma and evaluating the safety of MSCs in tumorigenesis.